Lisa Rohrbacher

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.

TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.

Journal: Leukemia
Published: December 10, 2025

TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity.

TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity.

Journal: Journal for immunotherapy of cancer
Published: November 17, 2025

FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell Exhaustion.

FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell Exhaustion.

Journal: Blood advances
Published: August 22, 2025

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

Journal: Blood advances
Published: August 22, 2025

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

Journal: Blood advances
Published: August 22, 2025

Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy.

Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy.

Journal: Cancer immunology, immunotherapy : CII
Published: September 24, 2024

Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse.

Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse.

Journal: Leukemia
Published: March 13, 2024

Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.

Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.

Journal: Cancer immunology, immunotherapy : CII
Published: May 08, 2023

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML.

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML.

Journal: Leukemia
Published: January 15, 2023

CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.

CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.

Journal: Cancer immunology, immunotherapy : CII
Published: December 18, 2022

Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.

Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.

Journal: Nature biotechnology
Published: March 30, 2022

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.

Journal: Blood
Published: March 21, 2022
Showing 1-12 of 15

Last Updated: 09/26/2026